Progress in Primary Aldosteronism 2019: New Players on the Block?
Authors:
Open Access
- 1 June 2020
- journal article
- editorial
- Published by Georg Thieme Verlag KG in Hormone and Metabolic Research
- Vol. 52 (6) , 345-346
Abstract
Primary aldosteronism (PA) is characterized by hypertension caused by inappropriately high adrenal aldosterone secretion, consecutively low plasma renin, and an elevated aldosterone to renin ratio. It is nowadays the universally accepted main cause of endocrine hypertension. According to the most recent epidemiological data, PA is present in 5.8% of unselected hypertensives in primary care, 6–12% of hypertensives treated in hypertension centers, and up to 30% in subjects with resistant hypertension [1]. Despite this high prevalence, a recent survey demonstrated that screening for PA is not universally followed. Renin and aldosterone measurements, the basis for PA screening, are currently performed by only 7% of general practitioners in Italy and 8% in Germany [2]. Accordingly, the prevalence of PA was low with 1% among hypertensives in Italy and 2% in Germany. In a retrospective cohort study of 4660 patients with resistant hypertension in California the screening rate for PA was 2.1% [3]. Based on these data, it is clear that we still miss the majority of PA cases, despite advances in diagnosis and therapy.Keywords
Funding Information
- Else Kröner-Fresenius Stiftung (2013_A182, 2015_A171)
- Else Kröner-Fresenius Stiftung (2019_A104)
- Deutsche Forschungsgemeinschaft to F.B. (BE2177/13-1)
- European Research Council (694913)
This publication has 20 references indexed in Scilit:
- Developments in Primary Aldosteronism Subtyping Using Steroid ProfilingHormone and Metabolic Research, 2020
- Atrial Fibrillation in Primary AldosteronismHormone and Metabolic Research, 2020
- Hypokalemia and the Prevalence of Primary AldosteronismHormone and Metabolic Research, 2020
- Primary Aldosteronism and Obstructive Sleep Apnea: Casual Association or Pathophysiological Link?Hormone and Metabolic Research, 2020
- Angiotensin II Type 1 Receptor Autoantibodies in Primary AldosteronismHormone and Metabolic Research, 2020
- Long-Term Mortality for Patients of Primary Aldosteronism Compared With Essential Hypertension: A Systematic Review and Meta-AnalysisFrontiers in Endocrinology, 2020
- Screening Rates for Primary Aldosteronism in Resistant HypertensionHypertension, 2020
- Prevalence, diagnosis and outcomes of treatment for primary aldosteronismBest Practice & Research Clinical Endocrinology & Metabolism, 2020
- Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysisThe Lancet Diabetes & Endocrinology, 2018
- Guidelines for primary aldosteronismJournal Of Hypertension, 2016